Literature DB >> 3069192

Canadian Consensus Conference on Cholesterol: final report. The Canadian Consensus Conference on the Prevention of Heart and Vascular Disease by Altering Serum Cholesterol and Lipoprotein Risk Factors.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3069192      PMCID： PMC1268502     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

Review 1.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Screening for hypercholesterolaemia in primary care: randomised controlled trial of postal questionnaire appraising risk of coronary heart disease.

Authors:  B Hutchison; S Birch; C E Evans; L J Goldsmith; B A Markham; J Frank; M Paterson
Journal:  BMJ       Date:  1998-04-18

3.  Sports Medicine: What family physicians see and what they need to learn.

Authors:  J M Lockyer; R T Strother; T Gondocz; G D Bell
Journal:  Can Fam Physician       Date:  1992-01       Impact factor: 3.275

4.  Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.

Authors:  S A Grover; M Dorais; G Paradis; J G Fodor; J J Frohlich; R McPherson; L Coupal; H Zowall
Journal:  CMAJ       Date:  2000-11-14       Impact factor: 8.262

5.  Atheromatous plaque reflects serum total cholesterol levels: a comparative morphologic study of endarterectomy coronary atherosclerotic plaques removed from patients from the southern part of India and Caucasians from Ottawa, Canada.

Authors:  P J Varghese; S B Arumugam; K M Cherian; V Walley; A Farb; R Virmani
Journal:  Clin Cardiol       Date:  1998-05       Impact factor: 2.882

6.  Is there an association among low untreated serum lipid levels, anger, and hazardous driving?

Authors:  K W Davidson; S S Reddy; P McGrath; D Zitner
Journal:  Int J Behav Med       Date:  1996

Review 7.  Risk-benefit assessment of drug treatment to prevent coronary heart disease. Estimating the benefits of risk factor modification.

Authors:  S A Grover; L Coupal
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

8.  Effects of mass transfer and reaction kinetics on serum cholesterol depletion rates of free and immobilized Pseudomonas pictorum.

Authors:  F A Garofalo; T M Chang
Journal:  Appl Biochem Biotechnol       Date:  1991-01       Impact factor: 2.926

9.  Modifying serum lipids to prevent coronary heart disease: do we have a consensus?

Authors:  S A Grover
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

10.  Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia.

Authors:  Genovefa D Kolovou; Katherine Anagnostopoulou; Nektarios D Pilatis; Klelia D Salpea; Ioannis S Hoursalas; Ilias Petropoulos; Helen I Bilianou; Dennis V Cokkinos
Journal:  Vasc Health Risk Manag       Date:  2005
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.